医学
荟萃分析
干细胞疗法
冲程(发动机)
科克伦图书馆
内科学
干细胞
缺血性中风
随机对照试验
临床试验
外科
缺血
移植
工程类
生物
机械工程
遗传学
作者
Yu Xiong,Xiumei Guo,Wen Gao,Chuhan Ke,Xinyue Huang,Zhigang Pan,Chuansheng Chen,Hanlin Zheng,Weipeng Hu,Feng Zheng,Hao Yao
出处
期刊:Medicine
[Wolters Kluwer]
日期:2024-03-22
卷期号:103 (12): e37414-e37414
标识
DOI:10.1097/md.0000000000037414
摘要
Background: Stem cell therapy on ischemic stroke has long been studied using animal experiments. The efficacy and safety of this treatment in ischemic stroke patients remain uncertain. Methods: We searched for all clinical randomized controlled trials published before October 2023, on PubMed, EMBASE, and the Cochrane Library using predetermined search terms, and performed a meta-analysis of the efficacy of stem cell therapy in ischemic stroke patients. Results: 13 studies that included 592 ischemic stroke patients were reviewed. The mRS (MD −0.32, 95% CI −0.64 to 0.00, I 2 = 63%, P = .05), NIHSS (MD −1.63, 95% CI −2.69 to −0.57, I 2 = 58%, P = .003), and BI (MD 14.22, 95% CI 3.95–24.48, I 2 = 43%, P = .007) showed effective stem cell therapy. The mortality (OR 0.42, 95% CI 0.23–0.79, I 2 = 0%, P = .007) showed improved prognosis and reduce mortality with stem cell therapy. Conclusion: Stem cell therapy reduces mortality and improves the neurological prognosis of ischemic stroke patients. However, due to the different types of stem cells used and the limited data in the reported studies, the safety of clinical applications of stem cells in patients with ischemic stroke must be carefully evaluated. Future randomized controlled trials with large sample sizes from controlled cell sources are warranted to validate this finding.
科研通智能强力驱动
Strongly Powered by AbleSci AI